top of page

Colorado Patients with Thyroid Eye Disease should read this.

I asked Chat GPT about Thyroid eye disease and Tepezza. This was the result. Chat GPT is an AI that reviews data and gives summary analysis of many different things. This is what Chat GPT's thoughts were which I thought was interesting.


Thyroid eye disease (TED), also known as Graves’ ophthalmopathy, is a condition that affects the eyes of people with an overactive thyroid gland. It can cause a range of symptoms, including eye pain, dryness, and redness, as well as bulging eyes, double vision, and even vision loss in severe cases.

Until recently, treatment options for TED were limited, with most patients receiving only supportive care or undergoing surgery to correct vision problems. However, in 2020, the FDA approved a new medication called Tepezza (teprotumumab-trbw) for the treatment of active TED, which has been shown to be a significant breakthrough in the management of this condition.

Tepezza is a monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), which is believed to play a key role in the development of TED. In clinical trials, Tepezza was found to be highly effective in reducing eye bulging and improving other symptoms of TED, with many patients experiencing significant improvements in just a few weeks of treatment.

One of the most significant studies on the efficacy of Tepezza was the Phase III OPTIC trial, which involved 83 patients with active, moderate-to-severe TED. The study found that patients who received Tepezza had a significantly greater reduction in eye bulging compared to those who received a placebo, with 71.4% of patients achieving a reduction in proptosis (eye bulging) of at least 2 mm, compared to just 20.0% of patients in the placebo group.

Furthermore, patients who received Tepezza also had significant improvements in other measures of TED severity, including clinical activity score, diplopia (double vision), and quality of life. Additionally, the effects of Tepezza were sustained over a long-term follow-up period of up to 48 weeks, with no significant safety concerns observed.

Another study that supports the use of Tepezza is a post-hoc analysis of the Phase II trial, which looked at the impact of the medication on patients with severe TED. The analysis found that patients with severe TED who received Tepezza had a greater reduction in proptosis and a higher rate of clinical response compared to those with less severe disease. This suggests that Tepezza may be particularly effective in patients with more advanced TED, who are often the most difficult to treat.

In summary, Tepezza is a highly effective medication for the treatment of active TED, with multiple studies demonstrating its ability to reduce eye bulging and improve other symptoms of the condition. While further research is needed to fully understand its long-term safety and efficacy, Tepezza represents a significant breakthrough in the management of TED and offers hope for patients who previously had limited treatment options.

32 views0 comments

Recent Posts

See All

Comments


bottom of page